Clinical trials: Leishmaniasis, Mucocutaneous
Leishmaniasis; Brazilian, Leishmaniasis, Mucocutaneous
Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly
Randomised clinical trial comparing oral miltefosine associated with pentoxifylline to intravenous liposomal amphotericin b for the treatment of cutaneous and mucosal leishmaniasis
- Trial name
- NCT06040489
- Testing
- Miltefosine 50mg, Pentoxifylline 400mg, Liposomal Amphotericin B
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- University of Brasilia
Cutaneous Leishmaniasis, American
Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis
Phase 2/3 randomized and controlled clinical trial, which will evaluate the effectiveness of the association meglumine antimoniate (Glucantime) with tofacitinib in the cure of CL and the capacity of this association to reduce the…
- Trial name
- CLTofa23 (NCT06011343)
- Testing
- Oral tofacitinib, Parenteral meglumine antimoniate
- Where
- Brazil
- Volunteers
- 22 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Mucosal Leishmaniasis
Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis With Inhaled Pentamidine Plus Oral Miltefosine
This is a phase 2 study of the combination of inhaled-pentamidine plus oral miltefosine for Bolivian mucosal leishmaniasis.
- Trial name
- NCT06550609
- Testing
- Miltefosine Oral Capsule
- Where
- Bolivia
- Volunteers
- 30 people
- Sponsor
- Fundacion Nacional de Dermatologia
Cutaneous Leishmaniasis, American
Feasibility and Usability of Mobile Applications for Monitoring Cutaneous Leishmaniasis Treatment in Colombia
An effectiveness-implementation sequential explanatory hybrid design type 2 was performed in two rural communities of Colombia. A quasi-experimental study with historical control (standard of care) was designed to estimate the…
- Trial name
- NCT05533736
- Testing
- Community based strategy to follow-up pactientes with Cutaneous Leishmaniasis
- Where
- Colombia
- Volunteers
- 105 people
- Sponsor
- Centro Internacional de Entrenamiento e Investigaciones Médicas
Leishmaniasis
The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil
Mucocutaneous leishmaniasis is endemic in the central region of Brazil and other countries worldwide. The standard treatment with meglumine antimoniate has a high rate of important adverse effects.
- Trial name
- NCT02530697
- Testing
- Meglumine antimoniate, Miltefosine, Pentoxifylline
- Where
- Brazil
- Volunteers
- 160 people
- Sponsor
- University of Brasilia
Mucosal Leishmaniasis, Cutaneous Leishmaniasis
Miltefosine to Treat Mucocutaneous Leishmaniasis
The purpose of this Treatment Investigational New Drug application was to make miltefosine available for mucocutaneous leishmaniasis patients presenting in the United States.
- Trial name
- NCT01050907
- Testing
- Miltefosine
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Knight Therapeutics (USA) Inc
Mucocutaneous Leishmaniasis
Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis
This study is a Phase 4, open-label, single group study in which at least 40 adult patients undergoing miltefosine treatment for mucocutaneous leishmaniasis (CL and ML) will be assessed by 12-lead ECG for prolongation of the…
- Trial name
- NCT02429518
- Testing
- Miltefosine
- Where
- Bolivia
- Volunteers
- 42 people
- Sponsor
- Knight Therapeutics (USA) Inc
Leishmaniasis, Leishmaniasis, Mucocutaneous
Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis
The purpose of this study is to determine whether miltefosine is effective in the treatment of mucosal leishmaniasis compared to meglumine antimoniate, the standard treatment.
- Trial name
- NCT01377974
- Testing
- Miltefosine, Standard Treatment Meglumine antimoniate
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Brasilia University Hospital
Cutaneous Leishmaniasis, Cutaneous Leishmaniasis, American
Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis
The goal of this clinical trial is to learn if the drug MILTEFOSINE, used topically in a hydrogel, works to treat non-complicated cutaneous leishmaniasis (CL) in adults.
- Conditions
- Cutaneous Leishmaniasis, Cutaneous Leishmaniasis, American, Topical Administration
- Trial name
- G-MTF01 (NCT07149753)
- Testing
- MILTEFOSINE gel
- Where
- Colombia
- Volunteers
- 15 people
- Sponsor
- Universidad Industrial de Santander
Cutaneous Leishmaniasis, American
Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly
A randomized controlled pilot trial with the aim of identifying the dose of liposomal amphotericin B associated with the highest cure rate in Cutaneous Leishmaniasis (CL).
- Trial name
- NCT06449040
- Testing
- Liposomal amphotericin B (AmBisome®)
- Where
- Brazil
- Volunteers
- 28 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Leishmaniasis; American, Cutaneous, Drug Side Effect
Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients
It is a randomized phase II clinical study, unicentre aimed to evaluate the tolerability, safety and efficacy of 18-Methoxyoronaridine as a candidate of tegumentary leishmaniasis treatment.
- Trial name
- NCT03084952
- Testing
- 18-Methoxycoronaridine, Glucantime
- Volunteers
- 52 people
- Sponsor
- Infan Industria Quimica Farmaceutica Nacional
Leishmaniasis, Mucocutaneous
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis
The purpose of this study is to evaluate the safety of the Leish-111f + MPL-SE vaccine given as three injections every 28 days at each of three dose levels of Leish-111f protein, in combination with standard pentavalent antimony…
- Trial name
- NCT00111514
- Testing
- Leish-111f + MPL-SE vaccine
- Where
- 2 sites in Peru
- Volunteers
- 48 people
- Sponsor
- Access to Advanced Health Institute (AAHI)
Cutaneous Leishmaniasis, American
Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis
Cure rate for L braziliensis bolivian CL has been 70%-80% for standard systemic and local monotherapies. It would benefit patients if cure rates could be consistently >90%, so testing a combination of two treatments is proposed.
- Trial name
- NCT03829917
- Testing
- Miltefosine and Paromomycin, miltefosine, paromomycin
- Where
- Bolivia
- Volunteers
- 120 people
- Sponsor
- Fundacion Nacional de Dermatologia
Kinetoplastid, Skin Diseases, Parasitic
Diagnosis and Treatment of Leishmania Infections
Patients admitted on this protocol must have an active Leishmania infection. The major objectives of the protocol are to diagnose and classify the Leishmania infection and to provide species-based therapy to study the natural…
- Conditions
- Kinetoplastid, Skin Diseases, Parasitic, Parasitic Diseases, Leishmaniasis
- Trial name
- NCT00344188
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mucosal Leishmaniasis
Treatment of Mucosal Bolivian Leishmaniasis
The purpose of this protocol is to conduct a randomized comparison of the efficacy and tolerance of miltefosine, LAMB, and pentavalent antimony for the treatment of mucosal leishmaniasis.
- Trial name
- NCT04799236
- Testing
- Group 1: Miltefosine, Group 2: Pentavalent Antimony, Group 3: Liposomal amphotericin B
- Where
- Bolivia
- Volunteers
- 120 people
- Sponsor
- Fundacion Nacional de Dermatologia
Mucocutaneous Leishmaniasis
Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis
This study is a Phase 4, open-label, single group study in which at least 55 evaluable adult male patients undergoing miltefosine treatment for mucocutaneous leishmaniasis will provide semen samples for spermiogram analysis of…
- Trial name
- NCT02431429
- Testing
- Miltefosine
- Where
- Bolivia
- Volunteers
- 55 people
- Sponsor
- Knight Therapeutics (USA) Inc
Leishmania Infantum Disease, Leishmaniasis, Visceral
LEISH-PED: Study on Leishmaniasis in Children
Leishmaniasis is an infection caused by Leishmania parasites. In children, it can affect the skin or internal organs. Diagnosis may be delayed because the signs and symptoms can be similar to those of other conditions.
- Conditions
- Leishmania Infantum Disease, Leishmaniasis, Visceral, Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous
- Trial name
- LEISH-PED (NCT07504757)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Meyer Children's Hospital IRCCS
Mucosal Leishmaniasis, Mucocutaneous Leishmaniasis
Low Antimonial Dosage in American Mucosal Leishmaniasis
"Phase III clinical trial for mucosal or mucocutaneous leishmaniasis. Equivalence between the standard and alternative schemes with meglumine antimoniate" has begun in October 2008 at the Laboratory of Leishmaniasis Surveillance…
- Trial name
- NCT01301937
- Testing
- Meglumine antimoniate
- Where
- Brazil
- Volunteers
- 76 people
- Sponsor
- Oswaldo Cruz Foundation
Leishmaniasis, Cutaneous, Leishmania Braziliensis Complex
Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia
This protocol will compare topical paromomycin to standard intralesional (IL) antimony (Sb) to placebo for L braziliensis in Bolivia.
- Conditions
- Leishmaniasis, Cutaneous, Leishmania Braziliensis Complex, Leishmaniasis, American, Leishmaniasis; American, Cutaneous
- Trial name
- NCT03096457
- Testing
- Paromomycin Sulfate, Pentamidine Isethionate
- Where
- 2 sites in Bolivia
- Volunteers
- 80 people
- Sponsor
- Fundacion Nacional de Dermatologia
Leishmaniasis
Miltefosine for Mucosal Leishmaniasis
This trial will study miltefosine as a treatment for mucosal leishmaniasis.
- Trial name
- NCT00373776
- Testing
- miltefosine 2.5 mg/kg/day for 28 days
- Where
- Bolivia
- Volunteers
- 75 people
- Sponsor
- AB Foundation